{"nctId":"NCT02833948","briefTitle":"Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)","startDateStruct":{"date":"2016-05"},"conditions":["Aortic Valve Stenosis","Cardiovascular Diseases","Heart Valve Diseases","Ventricular Outflow Obstruction","Thrombosis"],"count":231,"armGroups":[{"label":"ASA + Clopidogrel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Acetylsalicylic acid","Drug: Clopidogrel"]},{"label":"Rivaroxaban + ASA","type":"EXPERIMENTAL","interventionNames":["Drug: Acetylsalicylic acid","Drug: Rivaroxaban"]}],"interventions":[{"name":"Acetylsalicylic acid","otherNames":["Asprin"]},{"name":"Clopidogrel","otherNames":["Plavix"]},{"name":"Rivaroxaban","otherNames":["Xarelto"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Successful TAVR of a native aortic valve stenosis\n* By iliofemoral or subclavian access\n* With any approved/marketed TAVR device\n* Written informed consent\n\nExclusion Criteria:\n\n* Atrial fibrillation (AF), current or previous, with an ongoing indication for oral anticoagulant treatment\n* Any other indication for continued treatment with any oral anticoagulant\n* Known bleeding diathesis (such as but not limited to platelet count ≤ 50,000/mm3 at screening, hemoglobin level \\< 8.5 g/dL or \\< 5.3 mmol/l, history of intracranial hemorrhage, or subdural hematoma)\n* Any indication for dual antiplatelet therapy (DAPT) for more than three months after randomization (such as coronary, carotid, or peripheral stent implantation)\n* Clinically overt stroke within the last three months\n* Planned coronary or vascular intervention or major surgery\n* Severe renal insufficiency (eGFR \\< 30 mL/min/1.73 m2) or on dialysis, or post-TAVR unresolved acute kidney injury with renal dysfunction ≥ stage 2\n* Moderate and severe hepatic impairment (Child-Pugh Class B or C) or any hepatic disease associated with coagulopathy\n* Iodine contrast allergy or other condition that prohibits CT imaging","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan","description":"Reduced systolic leaflet excursion is classified as: (I) normal, (II) mildly reduced (\\<50%), (III) moderate to severely reduced (\\>50%), and (IV) immobile. Reduced systolic leaflet excursion is considered significant when it is \\> 50% or immobile. Quantitative assessment of leaflet motion is performed with a blood pool inversion volume rendered cine reconstruction throughout the cardiac cycle evaluating the bioprosthetic leaflets.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Rate of Prosthetic Leaflets With > 50% Motion Reduction as Assessed by Cardiac 4DCT-scan","description":"The rate of prosthetic leaflets with RLM\\> grade 3 as assessed by cardiac 4DCT","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"The Rate of Patients With at Least One Prosthetic Leaflet With Thickening as Assessed by Cardiac 4DCT-scan","description":"The rate of patients with at least one prosthetic leaflet with hypoattenuated leaflet thickening (HALT) as assessed by cardiac 4DCT.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"The Rate of Prosthetic Leaflets With Thickening as Assessed by Cardiac 4DCT-scan","description":"The rate of prosthetic leaflet with HALT as assessed by cardiac 4DCT-scan","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Aortic Transvalvular Mean Pressure Gradient (mmHg) as Determined by Transthoracic Echocardiography.","description":"Transprosthetic mean pressure gradiënt as determined by transthoracic echocardiography at three months after randomization.\n\nscale \\[0-100\\]","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":"5"},{"groupId":"OG001","value":"10","spread":"5"}]}]}]},{"type":"SECONDARY","title":"Effective Orifice Area (cm^2) as Determined by Transthoracic Echocardiography.","description":"Effective orifice area (cm2) as determined by transthoracic echocardiography at three months after randomization.\n\nscale \\[0.1-4.0\\]","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"0.4"},{"groupId":"OG001","value":"1.8","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT) - as Exploratory Analysis.","description":"Death, Dichotomization by HALT","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Death Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM)- as Exploratory Analysis.","description":"Death, Dichotomization by RLM","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (HALT)- as Exploratory Analysis.","description":"Thromboembolic event, Dichotomization by HALT","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Thromboembolic Event Assessed in the Main GALILEO Study and Analyzed in the GALILEO-4D Substudy With Regards to Occurence of the Leaflet Abnormalities (RLM) - as Exploratory Analysis.","description":"Thromboembolic event, Dichotomization by RLM","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":116},"commonTop":["minor bleeding"]}}}